Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Net Cash Flow (2022 - 2025)

Zentalis Pharmaceuticals has reported Net Cash Flow over the past 4 years, most recently at -$3.1 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$3.1 million for Q4 2025, up 58.53% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (down 63.95% YoY), and the annual figure for FY2025 was $2.1 million, down 63.95%.
  • Net Cash Flow for Q4 2025 was -$3.1 million at Zentalis Pharmaceuticals, down from $1.5 million in the prior quarter.
  • Over the last five years, Net Cash Flow for ZNTL hit a ceiling of $230.3 million in Q2 2023 and a floor of -$155.8 million in Q3 2023.
  • Median Net Cash Flow over the past 4 years was -$1.9 million (2024), compared with a mean of -$1.5 million.
  • Peak annual rise in Net Cash Flow hit 846.56% in 2023, while the deepest fall reached 16057.34% in 2023.
  • Zentalis Pharmaceuticals' Net Cash Flow stood at $518000.0 in 2022, then crashed by 16057.34% to -$82.7 million in 2023, then surged by 91.02% to -$7.4 million in 2024, then surged by 58.53% to -$3.1 million in 2025.
  • The last three reported values for Net Cash Flow were -$3.1 million (Q4 2025), $1.5 million (Q3 2025), and -$4.3 million (Q2 2025) per Business Quant data.